SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Perlegen
AFFX 14.010.0%Apr 1 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (21)10/28/2007 3:11:41 AM
From: Mike McFarland  Read Replies (1) of 27
 
three PR in past month:

Perlegen’s Contribution to Phase 2 Hapmap of Human Genetic Variation Empowers Scientists Studying Common Diseases. [PDF]
October 17, 2007

Breast Cancer Diagnostic Markers Licensed by Perlegen in Agreement with University of Cambridge and Cancer Research Technology. [PDF]
October 16, 2007

Perlegen and 454 to Collaborate in Drug Response Sequencing Study. [PDF]
October 2, 2007

perlegen.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News